Vaccination against human papillomavirus (HPV) is a safe and effective way to reduce prevalence of high-risk HPV infection, preventing cancers. Since the introduction of publicly-funded HPV vaccination in Canada in 2007, provincial and territorial programs have gone through numerous changes, impacting eligibility, vaccine type, and vaccine dosing.
The objective of this project is to assess the impact of the publicly-funded HPV vaccination program on cumulative vaccine coverage, population-level disease burden, and individual-level vaccine effectiveness for residents of Alberta.
